Genzyme CEO: Lemtrada's 'unique profile' raises new questions around MS
November 17, 2014 at 14:35 PM EST
The approval last week of the first-ever, once-a-year drug to treat multiple sclerosis may start to raise new questions in coming years about the nature of the disease and its treatment, according to Genzyme CEO David Meeker...